Palvella Therapeutics
PVLA
115 hedge funds and large institutions have $232M invested in Palvella Therapeutics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 54 increasing their positions, 11 reducing their positions, and 9 closing their positions.
391% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 11
300% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 9
30% more capital invested
Capital invested by funds: $179M → $232M (+$53.7M)
28% more funds holding
Funds holding: 90 → 115 (+25)
0.13% more ownership
Funds ownership: 0.66% → 0.79% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
75% less call options, than puts
Call options by funds: $244K | Put options by funds: $973K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.4M |
| 2 |
Millennium Management
New York
|
+$8.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$7.5M |
| 4 |
Renaissance Technologies
New York
|
+$6.81M |
| 5 |
Morgan Stanley
New York
|
+$5.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$13.2M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.25M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.23M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$974K |
| 5 |
Two Sigma Investments
New York
|
-$734K |
PVLA Hedge Fund Activity: Q1 2018 in Review
115 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2018, worth a combined $232M — up 30% from $179M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PVLA positions and 9 closed out — a net gain of 27 holders — while 54 added to existing stakes and 11 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $13.2M.
- 115 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2018, up from 90 in Q4 2017.
- Funds reported $232M of Palvella Therapeutics stock for Q1 2018, up 30% quarter-over-quarter.
- 36 funds opened new Palvella Therapeutics positions in Q1 2018 and 9 closed out, a net change of +27 holders.
- The largest Palvella Therapeutics buyer in Q1 2018 was Acadian Asset Management, an estimated $10.4M added.
- The largest Palvella Therapeutics seller in Q1 2018 was OrbiMed, an estimated $13.2M sold.
Based on aggregated 13F filings for Q1 2018.